title: Restoration of bone mass in the severely osteopenic senescent rat.
abstract: Studies in humans and rats suggest that age impairs the ability to form bone. This impairment may be due to a depletion or deficit in osteoprogenitor stem cells. Such a deficit would be expected to reduce the ability of the skeleton to respond to therapy designed to restore lost bone. This study evaluated whether severely osteopenic senescent rats are capable of responding to a potent anabolic factor in bone, prostaglandin E2 (PGE). Growing female Sprague Dawley rats were ovariectomized at 3 months and aged until the start of treatment at 23 months. Rats were treated daily with PGE (3 mg/kg sc) or vehicle for 56 days. Tibiae were harvested for bone histomorphometry and femora were obtained for mRNA analysis of bone matrix proteins. The cancellous bone area was fivefold greater in PGE-treated rats than in vehicle-treated controls and not different from age-matched ovary-intact rats. PGE approximately doubled the bone-forming surface and the mineral apposition rate and increased the bone formation rate fourfold. The increased cancellous bone area in PGE-treated rats was primarily due to an increase in osteoblasts over osteoclasts. One hundred percent of the endocortical surface and 72 +/- 9% of the periosteal surface of cortical bone was undergoing mineralization in PGE-treated rats, whereas no mineratization was evident in vehicle-treated rats. An architectural analysis of cancellous bone indicates that trabecular number and thickness were increased and separation decreased in the treated rats. Imaging by microcomputed tomography further revealed that with PGE treatment, trabeculae in the medial plane of the proximal tibial metaphysis were more robust and continuous with the endocortical surface. PGE also significantly induced message levels for the prepro-alpha (I) subunit of type I collagen (collagen), osteonectin, and osteocalcin. In summary, bone mass can be restored to severely osteopenic senescent rats, suggesting that aging does not necessarily diminish the capacity of the skeleton to form bone.
authors.affiliation: Department of Orthopedics, Mayo Clinic, Rochester, Minnesota 55905, USA. Sibonga.Jean@Mayo.edu
authors.forename: J D
authors.initials: JD
authors.lastname: Sibonga
authors.forename: M
authors.initials: M
authors.lastname: Zhang
authors.forename: E L
authors.initials: EL
authors.lastname: Ritman
authors.forename: R T
authors.initials: RT
authors.lastname: Turner
mesh_terms: D000375:Aging / Q000473:pathology / Q000502:physiology; D000818:Animals; D001851:Bone Diseases, Metabolic / Q000188:drug therapy*; D001857:Bone Matrix / Q000378:metabolism; D001842:Bone and Bones / Q000187:drug effects* / Q000473:pathology; D002113:Calcification, Physiologic / Q000187:drug effects; D016022:Case-Control Studies; D003094:Collagen / Q000032:analysis / Q000235:genetics; D015232:Dinoprostone / Q000627:therapeutic use*; D005260:Female; D005269:Femur / Q000187:drug effects / Q000473:pathology; D008852:Microradiography; D010006:Osteoblasts / Q000187:drug effects / Q000473:pathology; D015675:Osteocalcin / Q000032:analysis / Q000235:genetics; D010010:Osteoclasts / Q000187:drug effects / Q000473:pathology; D010012:Osteogenesis / Q000187:drug effects; D015676:Osteonectin / Q000032:analysis / Q000235:genetics; D010052:Ovariectomy; D010521:Periosteum / Q000187:drug effects / Q000473:pathology; D014677:Pharmaceutical Vehicles; D012333:RNA, Messenger / Q000032:analysis / Q000235:genetics; D051381:Rats; D017207:Rats, Sprague-Dawley; D013234:Stem Cells / Q000187:drug effects / Q000473:pathology; D013977:Tibia / Q000187:drug effects / Q000473:pathology; D014057:Tomography, X-Ray Computed
chemical_list: D015676:Osteonectin; D014677:Pharmaceutical Vehicles; D012333:RNA, Messenger; D015675:Osteocalcin; D003094:Collagen; D015232:Dinoprostone